Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07518706 | Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin | not yet recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Apr 9, 2026 | clinicaltrials |
| NCT07520357 | A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma | not yet recruiting | Phase 2 | 23 | Beijing GoBroad HospitalOTHER | 1 | Apr 9, 2026 |
| clinicaltrials |
| NCT07517640 | Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial | not yet recruiting | Phase 2 | 45 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07517653 | Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma | not yet recruiting | Phase 2 | 70 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 8, 2026 | clinicaltrials |
| NCT07493330 | Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL | not yet recruiting | Phase 1 / Phase 2 | 86 | Ruijin HospitalOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT07514429 | Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial(RELEVANT-HCC) | not yet recruiting | Phase 2 | 24 | Ju Hyun ShimOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07514455 | Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients(RECOMEND) | not yet recruiting | Phase 2 | 20 | Ju Hyun ShimOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07514533 | The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma | not yet recruiting | Phase 2 | 60 | Sir Run Run Shaw HospitalOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT07514767 | Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma(NOCANO) | not yet recruiting | Phase 2 | 60 | Prof. Lars Olaf CardellOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07514793 | Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma | not yet recruiting | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07515469 | A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT07515625 | Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT07515820 | SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study | not yet recruiting | Phase 2 | 12 | Meng QiuOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT07516210 | Adaptive Radiotherapy for Safe Hypofractionation(ART-Hypo) | not yet recruiting | Phase 2 | 264 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07510841 | JY016 Injection in Patients With Advanced Solid Tumors Expressing EGFR | not yet recruiting | Phase 1 / Phase 2 | 228 | Biotech Pharmaceutical Co., Ltd.OTHER | 0 | Apr 6, 2026 | clinicaltrials |
| NCT07510932 | Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)(FIRST-K) | not yet recruiting | Phase 2 | 88 | Korea University Anam HospitalOTHER | 0 | Apr 6, 2026 | clinicaltrials |
| NCT07511036 | PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma | not yet recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07511504 | Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 40 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06706219 | Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC | not yet recruiting | Phase 2 | 50 | Hunan Province Tumor HospitalOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07509398 | FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer | not yet recruiting | Phase 2 / Phase 3 | 220 | Shanghai 10th People's HospitalOTHER | 0 | Apr 3, 2026 | clinicaltrials |
| NCT07509424 | Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance | not yet recruiting | Phase 2 | 29 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 3, 2026 | clinicaltrials |
| NCT07509515 | QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. | not yet recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 0 | Apr 3, 2026 | clinicaltrials |
| NCT07510100 | Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(FUMANBA-04) | not yet recruiting | Phase 1 / Phase 2 | 17 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07510594 | A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC | not yet recruiting | Phase 2 | 48 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07506668 | RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas | not yet recruiting | Phase 1 / Phase 2 | 10 | Affiliated Hospital of Nantong UniversityOTHER | 0 | Apr 2, 2026 | clinicaltrials |
| NCT07507188 | Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)(INSTAR) | not yet recruiting | Phase 2 | 80 | Yonsei UniversityOTHER | 0 | Apr 2, 2026 | clinicaltrials |
| NCT07507526 | A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer(DTP-HER2) | not yet recruiting | Phase 2 | 76 | Sun Yat-sen UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07507825 | Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)(VHAG) | not yet recruiting | Phase 2 | 61 | First People's Hospital of HangzhouOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07507916 | Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 | 32 | Fudan UniversityOTHER | 0 | Apr 2, 2026 | clinicaltrials |
| NCT07505160 | Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients | not yet recruiting | Phase 2 | 35 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07505186 | Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 45 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07505849 | ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma | not yet recruiting | Phase 2 | 100 | KeshuZhouOTHER_GOV | 0 | Apr 1, 2026 | clinicaltrials |
| NCT07500285 | Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Phase II) | not yet recruiting | Phase 2 | 10 | Prof. Dr. Cemil Tascıoglu Education and Research Hospital OrganizationOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07503639 | Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 134 | Fudan UniversityOTHER | 0 | Mar 31, 2026 | clinicaltrials |
| NCT07504263 | Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies | not yet recruiting | Phase 1 / Phase 2 | 66 | Recurv Pharma IncINDUSTRY | 0 | Mar 31, 2026 | clinicaltrials |
| NCT07247201 | Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients(AlloNK1) | not yet recruiting | Phase 1 / Phase 2 | 31 | Singapore General HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07431216 | A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression | not yet recruiting | Phase 1 / Phase 2 | 68 | Starlight Therapeutics Inc.INDUSTRY | 0 | Mar 30, 2026 | clinicaltrials |
| NCT07499999 | Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer(BabyTEARS) | not yet recruiting | Phase 2 | 140 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07501104 | Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma(TRIUMPH-AM) | not yet recruiting | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 0 | Mar 30, 2026 | clinicaltrials |
| NCT07502014 | A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 60 | Huazhong University of Science and TechnologyOTHER | 0 | Mar 30, 2026 | clinicaltrials |
| NCT06418724 | Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma(NEOPECS) | not yet recruiting | Phase 2 | 27 | Melanoma and Skin Cancer Trials LimitedOTHER | 0 | Mar 27, 2026 | clinicaltrials |
| NCT07438600 | Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC(TianjinCIH) | not yet recruiting | Phase 2 | 38 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 27, 2026 | clinicaltrials |
| NCT07493980 | Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients | not yet recruiting | Phase 2 | 54 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07494435 | Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC | not yet recruiting | Phase 2 | 230 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07497074 | JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer | not yet recruiting | Phase 2 | 78 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07492121 | Screening for Brain Metastases(GAPIMET) | not yet recruiting | Phase 2 | 180 | University of ZurichOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06781125 | One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 72 | Immorna Biotherapeutics, Inc.INDUSTRY | 0 | Mar 24, 2026 | clinicaltrials |
| NCT07486648 | Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib(Precision) | not yet recruiting | Phase 1 / Phase 2 | 53 | Shanxi Province Cancer HospitalOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07489300 | Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer(BACON) | not yet recruiting | Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Mar 24, 2026 | clinicaltrials |
| NCT07489703 | SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC | not yet recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 0 | Mar 24, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 9, 2026source: clinicaltrials